Evidence summaries for semaglutide across type 2 diabetes, obesity, cardiovascular outcomes, kidney outcomes, safety, dosing, and comparative therapy.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
Replacing mealtime insulin with weekly semaglutide missed its primary glycaemic target (90% vs 75%, p=0.18) but cut weight and insulin dose in this small open-label trial. PICO summary and expert commentary.
A prespecified STRIDE subgroup analysis examined whether once-weekly semaglutide 1.0 mg improves walking distance consistently across diabetes characteristics in 792 adults with symptomatic PAD and type 2 diabetes. PICO summary and expert commentary.
An industry-sponsored indirect treatment comparison suggesting tirzepatide 10 and 15 mg achieve greater weight, BMI and HbA1c reduction than semaglutide 2.4 mg in type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.
A small 52-week single-centre randomised trial found once-weekly semaglutide shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
